Therefore, precise regulatory strategies targeting Cx43 must be tailored to specific tumor types and microenvironmental conditions, with optimal immunotherapeutic efficacy achievable only through differentiated intervention protocols. This evidence concerns the gene GJA1 and neoplasm.